Biotricity, Inc. (OTC:BTCY) Q1 2022 Earnings Conference Call August 16, 2021 4:30 PM ET Company Participants Mark Forney - MKR Investor Relations Waqaas Al-Siddiq - Founder & Chief Executive Officer John Ayanoglou - Chief Financial Officer Conference Call Participants David Larsen - BTIG Chet White - Helios Alpha Fund Operator Good day and welcome to the Biotricity's Fiscal First Quarter 2022 Financial Results Conference Call. Today's conference is being recorded. At this time, I would like to turn the conf ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ to_______________ Commission file number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its charter) Nevada 30-0983531 State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its charter) | --- | --- | |---------------------------------------------------------------------|---------------- ...

Biotricity, Inc. (OTC:BTCY) Q4 2021 Results Conference Call June 15, 2021 4:30 PM ET Company Participants Mark Forney - MKR IR Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - CFO Conference Call Participants Allen Klee - Maxim Group Operator Good day and welcome to the Biotricity Fourth Quarter and Fiscal 2021 Financial Results Conference Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Mark Forney of MRK Investor Relations. Please go ahead. Mark Forn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ to_______________ Commission file number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its charter) Nevada 30-0983531 State or ...

Biotricity, Inc. (OTC:BTCY) Q3 2021 Earnings Conference Call February 11, 2021 4:30 PM ET Company Participants Mark Forney - MKR IR Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - CFO Conference Call Participants Kyle Bauser - Colliers Securities Chris Jarrous - Dunlap Equity Jeff Porter - Porter Capital Management Liam Sherif - Platinum Point Capital Operator Good day and welcome to the Biotricity Fiscal Third Quarter 2021 Financial Results Conference Call. Today's conference is being recorded. At this ...

Biotricity, Inc. (OTC:BTCY) Q2 2021 Results Conference Call November 19, 2020 5:00 PM ET Company Participants Mark Forney - MKR Investor Relations Waqqas Al-Siddiq - CEO John Ayanoglou - CFO Conference Call Participants Kevin Dede - H.C. Wainwright Chris Jarrous - Dunlap Equity Operator Good day and welcome to the Biotricity's Fiscal Second Quarter 2021 Q2 Financial Results Conference Call. Today's conference is being recorded. And at this time, I would like to turn the conference over to Mark Forney, MKR I ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ to_______________ Commission file number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its charter) Nevada 30-0983531 State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ to_______________ Commission file number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its charter) Nevada 30-0983531 State or othe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-56074 BIOTRICITY INC. (Exact name of registrant as specified in its charter) | --- | --- | |---------------------------------------------------------------------|---------------- ...